Navigation Links
New Hepatitis C Treatment Shows Promise
Date:12/3/2009

Drug prevented virus from replicating in the livers of primates ,,

THURSDAY, Dec. 3 (HealthDay News) -- A new drug to treat hepatitis C has shown promise in a primate study.

The drug, called SPC3649, uses a new strategy to prevent the hepatitis C virus from replicating. Unlike other antivirals that target the virus itself, the new DNA-based drug targets a small RNA molecule in the liver that hepatitis C needs to replicate, the researchers explained.

By inhibiting the molecule, SPC3649 reduced hepatitis C virus levels in the liver and in the bloodstream in chimpanzees that received the highest dose by 350-fold.

Importantly, the virus showed no signs of resistance to SPC3649, developed by the Denmark-based company Santaris Pharma A/S. And levels of the virus remained low several months after the chimps had ended treatment, raising the possibility that the medicine would only need to be taken temporarily, the researchers added.

"It is a conceptually new approach. Instead of directly targeting the virus, the drug targeted a liver-specific molecule necessary for replication," said study author Robert Lanford, a scientist at the Southwest Foundation for Biomedical Research in San Antonio, Texas. "If we take that away from the virus, it can't replicate anymore."

Viruses replicate inside cells. Like small factories, they require all of the "machinery" inside the cell to accomplish this, explained Lanford. "The beauty of this drug is it takes away the host factor that the virus needs to replicate, and the virus cannot gain a mutation that allows it to be resistant to it."

The study appears in the Dec. 3 online edition of Science.

Hepatitis C, which is spread by contact with the blood of someone who is infected, infects the liver. About 70 percent to 80 percent of those with the virus have no symptoms initially, according to the U.S. Centers for Disease Control and Prevention. But over time, between 60 percent and 70 percent will develop chronic liver disease. Eventually, the virus can cause enough damage to the liver to lead to the formation of scar tissue, and eventually cirrhosis. The virus can also cause liver cancer.

There are about 170 million people infected with hepatitis C worldwide, according to background information in the study. Many don't know they have it.

The standard treatment is a two-drug cocktail of interferon, which makes the immune system more effective in eradicating the virus, and ribavirin, an antiviral, which cures about half of those infected, said Dr. Bruce Bacon, director of the division of gastroenterology and hepatology at Saint Louis University and co-director of the Saint Louis University Liver Center.

However, the side effects can be grueling, including flu-like symptoms, fatigue, depression and low white blood cell counts. Some patients have to be on the drugs for about six months, while some need about a year of treatment to kick the infection, Bacon said.

For those who don't respond to the two-drug cocktail, there are few options, Lanford said. Blacks are more likely to be among those in whom the treatments do not work, possibly due to genetic factors, Lanford noted.

SPC3649 may one day replace interferon, or be combined with the other drugs to augment it, Lanford said. Some evidence indicates it may work in those who don't respond to interferon. In the study, researchers gave four infected chimps SPC3649 intravenously for 12 weeks.

While the findings are exciting, the study involved only four chimps and there's a long way to go before this drug is ready for humans, Bacon said.

"What they have shown is successful reduction in the virus and no clear evidence of resistance, which are two of the major principals that need to be achieved with new therapies," Bacon said. "But what they have to prove now is whether this is a durable response. If you take the drug away, does the patient relapse."

Secondly, better treatments for hepatitis C are on the horizon. Phase 3 trials for two new protease inhibitors are wrapping up. The drugs have the potential to increase the cure rate to 70 percent to 80 percent when added to the two-drug interferon/ribavirin cocktail, Bacon said.

"The bar over which new discoveries much leap is that they have to have a better cure rate than the 70 or 80 percent we are going to see inside of two years," Bacon noted.

Phase 1 clinical trials for SPC3649 in people without hepatitis C are underway, Lanford said. Phase 2 trials in patients with hepatitis C should begin next year.

More information

The U.S. Centers for Disease Control and Prevention has more on hepatitis C.



SOURCES: Robert Lanford, Ph.D., scientist, Southwest Foundation for Biomedical Research, San Antonio, Texas; Bruce Bacon, M.D., director, division of gastroenterology and hepatology, Saint Louis University, and co-director, Saint Louis University Liver Center, St. Louis; Dec. 3, 2009, Science, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Nursing Society (ONS) wanted to create a communications platform that positions them as ... goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh news, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of ... college Bible teacher residing in North Carolina with his wife, Anna Marie. He and ... with six grandchildren. David is also the author of “Shadow and Substance.” , “Love, ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the ... located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the ... living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an ...
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA ... the complete 2016 Annual Accounts with notes. The report is ... in the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, ... Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media ...
Breaking Medicine Technology: